Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)

What this trial studies

To evaluate safety of lotilaner compared to vehicle control in the treatment of ocular rosacea.

Who can join: the full rules

Inclusion Criteria:

* 18 years of age or older at the time of consent.
* Has moderate to severe ocular rosacea
* Use of acceptable methods of contraception
* Are willing to sign the informed consent form and is deemed capable of complying with the requirements of the study protocol

Exclusion Criteria:

* Patient taking a topical or other therapy which may affect the patients rosacea
* Actively managed glaucoma or active ocular infection or ocular systemic disease
* Have hypersensitivity to lotilaner or any of the formulation components
* Are currently enrolled in an investigational drug or device study
* Are currently pregnant or lactating or planning to become pregnant during the study

Where it's running

• Site
  Houston, Texas, United States
• Site
  Lynchburg, Virginia, United States

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TP-06 for Persistent Corneal Epithelial Defects: see if healing improves

  This study tests TP-06 2.0% versus a vehicle to see if it helps adult patients with persistent corneal epithelial defects heal better.

  Recruiting at 6 sites Phase 2 Tarsus Pharmaceuticals, Inc. · Scottsdale, Arizona and 13 other locations · NCT07886268

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.